Genocea’s mission is to harness human biology to develop cancer immunotherapies for any patient by unlocking the targets that matter most. Our proprietary ATLAS™ technology is a clinically-validated platform that uniquely profiles the T cell repertoire and tumors, by selecting the therapeutically relevant antigens that drive powerful anti-tumor immune responses. ATLAS™ is the only platform able to identify Inhibigens™, or inhibitory antigens that dampen the immune response.

ATLAS™ drives Genocea’s emerging immunotherapy pipeline of best-in-class clinical stage programs. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Jul 29, 2021
Genocea Provides Second Quarter 2021 Corporate Update
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. READ MORE >
Jul 22, 2021
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, READ MORE >
Jul 13, 2021
Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy
CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial testing its GEN-011 READ MORE >

Event and Presentations

Genocea presents regularly at top-tier scientific and investor conferences.

Events image
Past Event
Jul 29, 2021 8:30 AM EDT
Second Quarter 2021 Financial Results
Listen to webcast
Events image
Past Event
Jun 24, 2021 9:00 AM EDT
Annual Shareholder Meeting
Listen to webcast

Corporate Governance

The Board of Directors of Genocea Biosciences (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Financials and Filings

Contact Us